Safety assessments
INTRAOCULAR PRESSURE
Differences in the BCVA and intraocular pressure (IOP) at baseline and the 12-week visit between the rebamipide treatment arms and the placebo group was the safety outcome measure. IOP was measured twice using non-contact tonometry, and if the difference between the two values was 2 mmHg or less, the average value was recorded. If the difference between the two values exceeded 2 mmHg, and additional measurement was obtained and the average value of the three measurements was recorded.